EpiPen's evolving market share

Adapted from Leerink Partners and IQVIA; Chart: Andrew Witherspoon/Axios

Brand-name EpiPen barely has any share of the epinephrine injection market these days — a swift change from 2015, when EpiPens controlled 89% of the market and Mylan earned congressional scrutiny for jacking up prices.

Yes, but: Mylan still owns the market through its "authorized" generic, which launched in 2016. That product is exactly the same as EpiPen, except for the label and its smaller price tag, and it has prevented other competing generics from gaining ground.

House passes a baby step on drug prices

A pair of EpiPen's on a table.
Photo: Alex Wong/Getty Images

The House yesterday overwhelmingly passed a bill cracking down on some of the tactics Mylan used to pay lower Medicaid rebates for the EpiPen. The Senate is hoping to pass the bill this year.

The big picture: EpiPen was misclassified as a generic drug within Medicaid, which resulted in Mylan paying less in rebates and causing taxpayers to overpay as much as $1.27 billion over 10 years, according to one government estimate.